Job title: Executive Director, Head of Biology
Marc Damelin is Executive Director, Head of Biology at Mersana Therapeutics, where he is focused on ADC discovery and development for oncology. Prior, he spent 10 years at Pfizer, where he led ADC discovery teams, oversaw the ADC portfolio and mentored two postdoctoral fellows. He is the Editor of the book “Innovations for Next-Generation Antibody-Drug Conjugates” published by Springer in 2018. Marc received his Ph.D. in Biophysics from Harvard University and was a Postdoctoral Fellow of the Damon Runyon Cancer Research Foundation at Columbia University.
Tumor Targeting of a STING Agonist by Means of an ADC Induces Anti-Tumor Immune Responses & Immunological Memory 4:00 pm
• Mersana has developed the Immunosynthen platform to enable tumor-targeted delivery of a STING agonist by means of an ADC • Demonstrating how targeted STING-agonist ADCs induce potent anti-tumor immune responses and immunological memory • Understanding how targeted STING-agonist ADCs cause significantly more anti-tumor activity and dramatically less induction of systemic cytokines than intravenously administered…Read more
day: Day Two